Cargando…
A Novel Synbiotic Alleviates Autoimmune Hepatitis by Modulating the Gut Microbiota-Liver Axis and Inhibiting the Hepatic TLR4/NF-κB/NLRP3 Signaling Pathway
Autoimmune hepatitis (AIH) is a liver disease characterized by chronic liver inflammation. The intestinal barrier and microbiome play critical roles in AIH progression. AIH treatment remains challenging because first-line drugs have limited efficacy and many side effects. Thus, there is growing inte...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134874/ https://www.ncbi.nlm.nih.gov/pubmed/36794950 http://dx.doi.org/10.1128/msystems.01127-22 |
_version_ | 1785031845381931008 |
---|---|
author | Kang, Yongbo Kuang, Xiaoyu Yan, Huan Ren, Peng Yang, Xiaodan Liu, Haixia Liu, Qingqing Yang, Hao Kang, Xing Shen, Xiaorong Tong, Mingwei Li, Lin Wang, Xiaohui Guo, Linzhi Ma, Jieqiong Zhang, Fan Fan, Weiping |
author_facet | Kang, Yongbo Kuang, Xiaoyu Yan, Huan Ren, Peng Yang, Xiaodan Liu, Haixia Liu, Qingqing Yang, Hao Kang, Xing Shen, Xiaorong Tong, Mingwei Li, Lin Wang, Xiaohui Guo, Linzhi Ma, Jieqiong Zhang, Fan Fan, Weiping |
author_sort | Kang, Yongbo |
collection | PubMed |
description | Autoimmune hepatitis (AIH) is a liver disease characterized by chronic liver inflammation. The intestinal barrier and microbiome play critical roles in AIH progression. AIH treatment remains challenging because first-line drugs have limited efficacy and many side effects. Thus, there is growing interest in developing synbiotic therapies. This study investigated the effects of a novel synbiotic in an AIH mouse model. We found that this synbiotic (Syn) ameliorated liver injury and improved liver function by reducing hepatic inflammation and pyroptosis. The Syn reversed gut dysbiosis, as indicated by an increase in beneficial bacteria (e.g., Rikenella and Alistipes) and a decrease in potentially harmful bacteria (e.g., Escherichia-Shigella) and lipopolysaccharide (LPS)-bearing Gram-negative bacterial levels. The Syn maintained intestinal barrier integrity, reduced LPS, and inhibited the TLR4/NF-κB and NLRP3/Caspase-1 signaling pathway. In addition, microbiome phenotype prediction by BugBase and bacterial functional potential prediction using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) showed that Syn improved gut microbiota function involving inflammatory injury, metabolism, immune response, and pathopoiesia. Furthermore, the new Syn was as effective as prednisone against AIH. Therefore, this novel Syn could be a candidate drug for alleviating AIH through its anti-inflammatory and antipyroptosis properties that relieve endothelial dysfunction and gut dysbiosis. IMPORTANCE Synbiotics can ameliorate liver injury and improve liver function by reducing hepatic inflammation and pyroptosis. Our data indicate that our new Syn not only reverses gut dysbiosis by increasing beneficial bacteria and decreasing lipopolysaccharide (LPS)-bearing Gram-negative bacteria but also maintains intestinal barrier integrity. Thus, its mechanism might be associated with modulating gut microbiota composition and intestinal barrier function by inhibiting the TLR4/NF-κB/NLRP3/pyroptosis signaling pathway in the liver. This Syn is as effective as prednisone in treating AIH without side effects. Based on these findings, this novel Syn represents a potential therapeutic agent for AIH in clinical practice. |
format | Online Article Text |
id | pubmed-10134874 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-101348742023-04-28 A Novel Synbiotic Alleviates Autoimmune Hepatitis by Modulating the Gut Microbiota-Liver Axis and Inhibiting the Hepatic TLR4/NF-κB/NLRP3 Signaling Pathway Kang, Yongbo Kuang, Xiaoyu Yan, Huan Ren, Peng Yang, Xiaodan Liu, Haixia Liu, Qingqing Yang, Hao Kang, Xing Shen, Xiaorong Tong, Mingwei Li, Lin Wang, Xiaohui Guo, Linzhi Ma, Jieqiong Zhang, Fan Fan, Weiping mSystems Research Article Autoimmune hepatitis (AIH) is a liver disease characterized by chronic liver inflammation. The intestinal barrier and microbiome play critical roles in AIH progression. AIH treatment remains challenging because first-line drugs have limited efficacy and many side effects. Thus, there is growing interest in developing synbiotic therapies. This study investigated the effects of a novel synbiotic in an AIH mouse model. We found that this synbiotic (Syn) ameliorated liver injury and improved liver function by reducing hepatic inflammation and pyroptosis. The Syn reversed gut dysbiosis, as indicated by an increase in beneficial bacteria (e.g., Rikenella and Alistipes) and a decrease in potentially harmful bacteria (e.g., Escherichia-Shigella) and lipopolysaccharide (LPS)-bearing Gram-negative bacterial levels. The Syn maintained intestinal barrier integrity, reduced LPS, and inhibited the TLR4/NF-κB and NLRP3/Caspase-1 signaling pathway. In addition, microbiome phenotype prediction by BugBase and bacterial functional potential prediction using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) showed that Syn improved gut microbiota function involving inflammatory injury, metabolism, immune response, and pathopoiesia. Furthermore, the new Syn was as effective as prednisone against AIH. Therefore, this novel Syn could be a candidate drug for alleviating AIH through its anti-inflammatory and antipyroptosis properties that relieve endothelial dysfunction and gut dysbiosis. IMPORTANCE Synbiotics can ameliorate liver injury and improve liver function by reducing hepatic inflammation and pyroptosis. Our data indicate that our new Syn not only reverses gut dysbiosis by increasing beneficial bacteria and decreasing lipopolysaccharide (LPS)-bearing Gram-negative bacteria but also maintains intestinal barrier integrity. Thus, its mechanism might be associated with modulating gut microbiota composition and intestinal barrier function by inhibiting the TLR4/NF-κB/NLRP3/pyroptosis signaling pathway in the liver. This Syn is as effective as prednisone in treating AIH without side effects. Based on these findings, this novel Syn represents a potential therapeutic agent for AIH in clinical practice. American Society for Microbiology 2023-02-16 /pmc/articles/PMC10134874/ /pubmed/36794950 http://dx.doi.org/10.1128/msystems.01127-22 Text en Copyright © 2023 Kang et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Kang, Yongbo Kuang, Xiaoyu Yan, Huan Ren, Peng Yang, Xiaodan Liu, Haixia Liu, Qingqing Yang, Hao Kang, Xing Shen, Xiaorong Tong, Mingwei Li, Lin Wang, Xiaohui Guo, Linzhi Ma, Jieqiong Zhang, Fan Fan, Weiping A Novel Synbiotic Alleviates Autoimmune Hepatitis by Modulating the Gut Microbiota-Liver Axis and Inhibiting the Hepatic TLR4/NF-κB/NLRP3 Signaling Pathway |
title | A Novel Synbiotic Alleviates Autoimmune Hepatitis by Modulating the Gut Microbiota-Liver Axis and Inhibiting the Hepatic TLR4/NF-κB/NLRP3 Signaling Pathway |
title_full | A Novel Synbiotic Alleviates Autoimmune Hepatitis by Modulating the Gut Microbiota-Liver Axis and Inhibiting the Hepatic TLR4/NF-κB/NLRP3 Signaling Pathway |
title_fullStr | A Novel Synbiotic Alleviates Autoimmune Hepatitis by Modulating the Gut Microbiota-Liver Axis and Inhibiting the Hepatic TLR4/NF-κB/NLRP3 Signaling Pathway |
title_full_unstemmed | A Novel Synbiotic Alleviates Autoimmune Hepatitis by Modulating the Gut Microbiota-Liver Axis and Inhibiting the Hepatic TLR4/NF-κB/NLRP3 Signaling Pathway |
title_short | A Novel Synbiotic Alleviates Autoimmune Hepatitis by Modulating the Gut Microbiota-Liver Axis and Inhibiting the Hepatic TLR4/NF-κB/NLRP3 Signaling Pathway |
title_sort | novel synbiotic alleviates autoimmune hepatitis by modulating the gut microbiota-liver axis and inhibiting the hepatic tlr4/nf-κb/nlrp3 signaling pathway |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134874/ https://www.ncbi.nlm.nih.gov/pubmed/36794950 http://dx.doi.org/10.1128/msystems.01127-22 |
work_keys_str_mv | AT kangyongbo anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT kuangxiaoyu anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT yanhuan anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT renpeng anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT yangxiaodan anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT liuhaixia anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT liuqingqing anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT yanghao anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT kangxing anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT shenxiaorong anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT tongmingwei anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT lilin anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT wangxiaohui anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT guolinzhi anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT majieqiong anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT zhangfan anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT fanweiping anovelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT kangyongbo novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT kuangxiaoyu novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT yanhuan novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT renpeng novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT yangxiaodan novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT liuhaixia novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT liuqingqing novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT yanghao novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT kangxing novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT shenxiaorong novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT tongmingwei novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT lilin novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT wangxiaohui novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT guolinzhi novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT majieqiong novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT zhangfan novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway AT fanweiping novelsynbioticalleviatesautoimmunehepatitisbymodulatingthegutmicrobiotaliveraxisandinhibitingthehepatictlr4nfkbnlrp3signalingpathway |